Artiva Biotherapeutics
Biotechnology Research • 
San Diego, California, United States • 101-200 Employees
Company overview
| Headquarters | 5505 Morehouse Drive, Suite 100, San Diego, California 92121, US |
| Phone number | +18582674467 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Cancer, Cell Therapy, Nk Cell Therapy, Nk Cells, Car-Nk |
| Founded | 2019 |
| Employees | 101-200 |
| Socials |
Key Contacts at Artiva Biotherapeutics
Daniel De Moraes Branco
Senior Director Of Corporate Development And Latam Medical Affairs Lead
Michael Saddekni
Executive Medical Director, Clinical Development
Katy Swanson
Sr. Director, Clinical Operations
Robert Goertsches
Executive Director Medical Affairs Europe
Aung Lwin
Senior Director Quality Control
Christopher Kuehn
Director Project Management
Lisa Guerrettaz
Executive Director
Amanda Medcalf Conerty
Executive Director, Manufacturing, Advocacy And Engagement
Sharon Rittenhouse
Sr. Director, Data Management
Anne Lamontagne
Senior Director Regulatory Affairs Cmc
Artiva Biotherapeutics Email Formats
Artiva Biotherapeutics uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@artivabio.com), used 66.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@artivabio.com | 66.1% |
{first name}{last name} | johndoe@artivabio.com | 19.4% |
{2char} | {2char}@artivabio.com | 8.1% |
{last name}{last name} | doedoe@artivabio.com | 4.8% |
{first initial}{first initial} | jj@artivabio.com | 1.6% |
About Artiva Biotherapeutics
Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.
Artiva Biotherapeutics revenue & valuation
| Annual revenue | $251,000 |
| Revenue per employee | $3,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $803,200 |
| Total funding | $287,000,000 |
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Artiva Biotherapeutics has 49 employees across 10 departments.
Departments
Number of employees
Funding Data
Explore Artiva Biotherapeutics's funding history, including investment rounds, total capital raised, and key backers.
Artiva Biotherapeutics Tech Stack
Discover the technologies and tools that power Artiva Biotherapeutics's digital infrastructure, from frameworks to analytics platforms.
Analytics
JavaScript libraries
Maps
JavaScript libraries
Analytics
JavaScript libraries
JavaScript libraries
Programming languages
Security
Blogs
Analytics
SEO
United Kingdom
Spain
South Africa
Frequently asked questions
4.8
40,000 users
